Business
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
REDWOOD CITY, Calif., October 28, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held from November 10-12, 2025 in Boston.
About this update from Adicet Bio, Inc.
REDWOOD CITY, Calif., October 28, 2025 --( BUSINESS WIRE )--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held from November 10-12, 2025 in Boston. Details of the event are as follows: Date: Tuesday, November 11, 2025 Time: 3:00 p.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com . An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20251028026101/en/ Contacts Adicet Bio, Inc. Investor and Media Contacts Anne Bowdidge [email protected] Penelope Belnap Precision AQ 212-362-1200 [email protected]